Report: Pfizer coronavirus vaccine could be available for kids under 5 in February

The Pfizer-BioNTech coronavirus vaccine could become available for children younger than 5 by the end of February, people familiar with the matter told The Washington Post on Monday. This would be the first vaccine made available for the age group in the United States.
The companies are expected to soon submit a request to the Food and Drug Administration for emergency-use authorization of the vaccine in kids 6 months to 5 years old, the Post reports. Once the FDA receives the application, regulators will begin reviewing the trial data on the two-shot regimen; data on a third shot won't be available until the end of March, at the earliest. The FDA's outside advisers will likely meet on the authorization request in mid-February, the Post reports.
Pfizer and BioNTech shared in December that two doses of its vaccine in 2-, 3-, and 4-year-olds didn't trigger the same type of immune response as seen in teens and adults, but did for children 6 months to 2 years old. During the trial, the kids received two doses of 3-microgram shots — a tenth of the dose given to adults — three weeks apart. Read more at The Washington Post.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
How Canadian tariffs could impact tourism to the US
In the Spotlight Canadians represent the largest group of foreign visitors to the United States. But they may soon stop visiting.
By Justin Klawans, The Week US Published
-
Entitlements: DOGE goes after Social Security
Feature Elon Musk is pushing false claims about Social Security fraud
By The Week US Published
-
The Week contest: Amazon Bond
Puzzles and Quizzes
By The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published